Analyst: Genmab's progress with the FDA sends a positive signal

It's not surprising that the US FDA has accepted Genmab's application for the drug tisotumab vedotin, but it's a feather in the company's cap that the application received priority review status.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Genmab will probably manage better than the general stock market on Monday following the firm's Friday announcement that the US Food and Drug Administration (FDA) has accepted treating its – and Seagen's – biologics license application for the drug tisotumab vedotin in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading